Post-hoc analysis found that, despite continued titration with insulin glargine, more diabetes patients achieved sustained glycemic control with exenatide once-weekly, according to data presented at the Annual Meeting of the European Association for the Study of Diabetes (EASD) in Vienna, Austria.
Post-hoc analysis found that, despite continued titration with insulin glargine, more diabetes patients achieved sustained glycemic control with exenatide once-weekly, according to data presented at the Annual Meeting of the European Association for the Study of Diabetes (EASD) in Vienna, Austria.
Three-year data from the DURATION-3 trial, sponsored by AstraZeneca, were studied to explore the association between baseline characteristics or early (≤12 week) treatment responses with sustained glycaemic control, comparing exenatide once-weekly with titrated insulin glargine (glargine). Patients received exenatide once-weekly (n=233) or glargine (n=223) as add-on therapy to metformin alone or in combination with a sulphonylurea. Inability to achieve sustained glycaemic response was defined as HbA1c > 7% at 2 consecutive visits or HbA1c > 9% at 1 visit after 26 weeks of treatment.
In particular, the results showed the following:
· In the intent-to-treat patient population, 50% of the exenatide once weekly group achieved sustained glycemic control compared to 43% in the glargine group. Of those who completed 3 years, 43% and 33% respectively, achieved sustained glycemic control.
· Regardless of therapy, for every 1% elevation in baseline HbA1c (> 7%) the risk of losing glycaemic control increased by 90% (P=.0002).
· For every 10% higher baseline HOMA-B, the risk of losing glycaemic control decreased by 11% (P=.0288).
· The rate of weight change in weeks 1 through 8 was the most relevant early treatment response predictor of HbA1c control (P =.0640).
Baseline HbA1c and HOMA-B significantly impacted the odds of patients achieving sustained control.
Additionally, the results suggest the rate of weight change following treatment initiation [weeks 1 through 8] may potentially predict the probability of patients achieving longer-term sustained glycemic control in adult patients with type 2 diabetes, according to the study.
Navitus to Offer Unbranded Stelara Biosimilar, Remove Stelara from Formulary
March 13th 2025Lumicera Health Services, Navitus’ specialty pharmacy, has made a deal with Teva to offer an unbranded biosimilar that they estimate will save $112,000 and $336,000 per patient per year. Navitus will remove Stelara from formulary on July 1, 2025.
Read More
FDA Approves Neffy 1 mg Nasal Spray for Pediatric Patients
March 6th 2025Neffy 1 mg is now approved by the FDA to treat pediatric patients who weigh 33 to 65 lbs. Neffy was first FDA-approved as a 2 mg dose in August 2024 for the emergency treatment of anaphylaxis in children and adults weighing at least 66 lbs.
Read More